Bifosfonaten verhogen risico op fracturen!

Ondanks alle schone theorieën en propaganda van de firma Merck duiken er steeds meer studies op die melden dat het risico op spontane heupfracturen hoger ligt bij (vooral) vrouwen die enkele jaren bifosfonaten innemen ter behandeling van osteoporose.

Beste bezoeker

Gelieve u aan te melden om dit artikel te lezen. Registreer u hier, snel en gratis!

Trefwoorden:

Auteur

Marleen Nys

Referentie(s)

Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010 Mar;8(1):34-9.

Lenart BA et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009 Aug;20(8):1353-62.

Goddard MS et al. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009 Aug;32(8) 624-27.

Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009 Jul;467(7):1921-6.

Bamrungsong T, Pongchaiyakul C. Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. J Med Assoc Thai. 2010 May;93(5):620-4.

Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009 Nov;91(11):2556-61.

Kwek EB et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008 Feb;39(2):224-31.

Guerra-García MM et al. Incidence of hip fractures due to osteoporosis in relation to the precription of drugs for their prevention and treatment in Galicia, Spain. Aten Primaria. 2010 Jun 14. [Epub ahead of print]